SG11201809973YA - Hot melt extrusion composition using direct compressible excipient as plasticizer - Google Patents

Hot melt extrusion composition using direct compressible excipient as plasticizer

Info

Publication number
SG11201809973YA
SG11201809973YA SG11201809973YA SG11201809973YA SG11201809973YA SG 11201809973Y A SG11201809973Y A SG 11201809973YA SG 11201809973Y A SG11201809973Y A SG 11201809973YA SG 11201809973Y A SG11201809973Y A SG 11201809973YA SG 11201809973Y A SG11201809973Y A SG 11201809973YA
Authority
SG
Singapore
Prior art keywords
international
plasticizer
melt extrusion
darmstadt
pct
Prior art date
Application number
SG11201809973YA
Other languages
English (en)
Inventor
Dieter Lubda
Mengyao Zheng
Alessandro Elia
Gallo Nicole Di
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of SG11201809973YA publication Critical patent/SG11201809973YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00Use of organic ingredients
    • C08K5/04Oxygen-containing compounds
    • C08K5/05Alcohols; Metal alcoholates
    • C08K5/053Polyhydroxylic alcohols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00Use of organic ingredients
    • C08K5/0008Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/0016Plasticisers
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L29/00Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers
    • C08L29/02Homopolymers or copolymers of unsaturated alcohols
    • C08L29/04Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Extrusion Moulding Of Plastics Or The Like (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201809973YA 2016-05-13 2017-05-10 Hot melt extrusion composition using direct compressible excipient as plasticizer SG11201809973YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16169693 2016-05-13
PCT/EP2017/061126 WO2017194576A1 (en) 2016-05-13 2017-05-10 Hot melt extrusion composition using direct compressible excipient as plasticizer

Publications (1)

Publication Number Publication Date
SG11201809973YA true SG11201809973YA (en) 2018-12-28

Family

ID=56134085

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201809973YA SG11201809973YA (en) 2016-05-13 2017-05-10 Hot melt extrusion composition using direct compressible excipient as plasticizer

Country Status (12)

Country Link
US (1) US11510986B2 (ko)
EP (1) EP3454836A1 (ko)
JP (1) JP6955517B2 (ko)
KR (1) KR102358069B1 (ko)
CN (1) CN109152739B (ko)
BR (1) BR112018071673B1 (ko)
CA (1) CA3023800A1 (ko)
IL (1) IL262908B (ko)
MX (1) MX2018012999A (ko)
PH (1) PH12018502055A1 (ko)
SG (1) SG11201809973YA (ko)
WO (1) WO2017194576A1 (ko)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2542346B2 (ja) 1987-05-30 1996-10-09 日本合成化学工業株式会社 高重合度ポリビニルアルコ−ルの製造法
JP2577698B2 (ja) * 1993-08-05 1997-02-05 信道 中野 流動性の高いソルビトール粉末の製造方法
DE19617487A1 (de) * 1996-05-02 1997-11-06 Merck Patent Gmbh Geschmacksverbesserung von Arzneimittelwirkstoffen
JP4783278B2 (ja) * 2003-02-03 2011-09-28 ノバルティス アーゲー 医薬製剤
US20080311240A1 (en) * 2004-06-17 2008-12-18 Cargill Incorporated Steam Agglomeration of Polyols
BRPI0714963A2 (pt) * 2006-08-16 2013-07-30 Novartis Ag processo de fabricaÇço de dispersÕes sàlidas de compostos terapÊuticos altamente cristalinos
ES2720626T3 (es) * 2008-06-20 2019-07-23 Merck Patent Gmbh Combinación de poliol compresible directamente
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
ES2655719T3 (es) * 2009-07-10 2018-02-21 Merck Patent Gmbh Sustancia auxiliar con bajo contenido de agua para formación de comprimidos y procedimiento para su fabricación
US8551529B2 (en) * 2009-07-10 2013-10-08 Merck Patent Gmbh Composition for the production of tablets, and method for the production of said composition
GB201020895D0 (en) * 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form
CN102204868B (zh) * 2011-05-18 2014-01-22 北京化工大学 采用多元辅料制备吲哚美辛速释制剂的热熔挤出工艺
RU2013155713A (ru) * 2011-07-06 2015-08-20 Профибрикс Бв Составы для лечения ран
US20130071476A1 (en) * 2011-08-19 2013-03-21 Subraman Rao Cherukuri Rapid Melt Controlled Release Taste-Masked Compositions
CN105012242A (zh) * 2015-07-21 2015-11-04 南京中医药大学 一种厚朴酚或和厚朴酚或两者混合物固体分散体及其热熔挤出制备方法

Also Published As

Publication number Publication date
PH12018502055A1 (en) 2019-06-24
BR112018071673A2 (pt) 2019-02-19
WO2017194576A1 (en) 2017-11-16
IL262908A (en) 2018-12-31
US11510986B2 (en) 2022-11-29
CN109152739B (zh) 2022-09-30
IL262908B (en) 2022-04-01
US20200254098A1 (en) 2020-08-13
KR20190008556A (ko) 2019-01-24
BR112018071673B1 (pt) 2024-02-27
KR102358069B1 (ko) 2022-02-03
JP2019515006A (ja) 2019-06-06
EP3454836A1 (en) 2019-03-20
CN109152739A (zh) 2019-01-04
JP6955517B2 (ja) 2021-10-27
MX2018012999A (es) 2019-01-28
CA3023800A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201810366WA (en) 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
SG11201805940QA (en) Benzopyrazole compounds and analogues thereof
SG11201907435PA (en) Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201901558VA (en) Pth compounds with low peak-to-trough ratios
SG11201900633XA (en) Piperidine cxcr7 receptor modulators
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201901986SA (en) Process for the manufacture of a solid pharmaceutical adminstration form
SG11201809172WA (en) Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201803918VA (en) Production of steviol glycosides in recombinant hosts
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201909807TA (en) Methods of manufacturing of niraparib
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201407184PA (en) Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases
SG11202000494UA (en) Drug delivery composition
SG11201809882XA (en) Pharmaceutical combinations for treating cancer
SG11201809970UA (en) Use of amino sugar as plasticizer
SG11201909906QA (en) Organic compounds
SG11201909059XA (en) Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
SG11201910043PA (en) Manufacture of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] and compositions thereof